FEMS Immunology and Medical Microbiology 40 (2004) 207^213 www.fems-microbiology.org CD14 gene promoter polymorphism in di¡erent clinical forms of tuberculosis Eugenia Pacheco 1 , Carolina Fonseca 1 , Carlos Montes, Jovanny Zabaleta 2 , Luis F. Garc|¤a, Mauricio A. Arias Grupo de Inmunolog|¤a Celular e Inmunogene¤tica, Facultad de Medicina, Universidad de Antioquia, Cra 51 D No 62-29 Lab 283 Medell|¤n, Colombia Received 8 September 2003; received in revised form 6 November 2003 ; accepted 12 November 2003 First published online 14 January 2004 Abstract Mycobacterium tuberculosis interacts with monocyte^macrophages through cell surface molecules including CD14. A soluble form of CD14 (sCD14) exists in human serum, and higher amounts of it are found in tuberculosis. A polymorphism on CD14 gene promoter was associated with increased sCD14 levels in some diseases. To evaluate whether this polymorphism associates with tuberculosis, its clinical forms, and increased sCD14, genotype/allele frequencies in tuberculosis patients were compared with the controls. Results confirmed increased levels of sCD14 in patients with tuberculosis, and those with miliary tuberculosis had the highest levels. sCD14 decreased to normal levels after anti-tuberculosis treatment. No association was found between the CD14 polymorphism and tuberculosis or sCD14 levels. Results suggest that sCD14 may be involved in anti-tuberculosis immune response, but its increase is a consequence of infection rather than a predisposed genetic trait. Measuring sCD14 in tuberculosis may help monitor anti-tuberculosis treatment. 9 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved. Keywords : Tuberculosis ; Soluble CD14; Polymorphism; Polymerase chain reaction-restriction fragment length polymorphism 1. Introduction Tuberculosis (TB) is an infectious disease of high prevalence worldwide. The World Health Organization reported on estimated 8.3 million new TB cases in the world in the year 2000, and more than 1.8 million people died from TB that year [1]. The responsible pathogen, Mycobacterium tuberculosis, has the ability to survive within the host phagocytic cells, and the interaction between the host and the bacteria may result in tissue damage characterised by granuloma formation, tissue necrosis with formation of cavities and, eventually, dissemination of the disease [2]. M. tuberculosis, similarly as an array of di¡erent Gram- * Corresponding author. Tel. : +57 (4) 510 6098; Fax : +57 (4) 510 6079. E-mail address : marias@medicina.udea.edu.co (M.A. Arias). 1 The ¢rst two authors contributed equally to this study. Present address: Department of Pathology and Tumor Immunology Program, Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, 533 Bolivar St, CSRB 455, New Orleans, LA 70112 USA. 2 negative and Gram-positive bacteria, interacts with monocyte^macrophages through several cell surface molecules including CD14. This is a glycosylphosphatidylinositollinked cell surface molecule [3], which, after interacting with either whole bacteria [4] or cell wall components such as lipopolysaccharide (LPS) from Gram-negative bacteria and lipoarabinomannans (LAM) from mycobacteria [5,6], mediates cell activation upon triggering Tolllike receptors [6]. Cell activation results in release of pro-in£ammatory molecules such as tumor necrosis factor (TNF)-K, interleukin (IL)-6, IL-1L, nitric oxide, oxygen radicals, and complement components [7,8], which up-regulate host defence mechanisms that participate in eliminating bacterial infection. However, high production of these molecules may cause profound deleterious e¡ects, including septic shock and death [8]. A soluble form of CD14 (sCD14) also exists, which lacks the glycosylphosphatidylinositol anchor [9]. sCD14 seems to be produced by both monocytes [10] and hepatocytes [11,12], as well as endothelial cells [13], and considerably high amounts (2^3 Wg ml31 ) are found in the serum of healthy individuals [14]. The known functional relevance of sCD14 is its mediation of bacteria-induced 0928-8244 / 04 / $22.00 9 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved. doi:10.1016/S0928-8244(03)00369-9 FEMSIM 1661 10-3-04 208 E. Pacheco et al. / FEMS Immunology and Medical Microbiology 40 (2004) 207^213 cell activation of both membrane CD14 (mCD14)-negative [15,16] and mCD14-positive cells [17]. Activation via sCD14 induces the same pro-in£ammatory e¡ects secondary to the interaction of LPS or bacterial cell wall components with mCD14. Increased levels of serum sCD14 have been found in non-infectious and infectious diseases such as reumathoid arthritis [18], systemic lupus erythematosus [19], polytraumatised and severely burned patients [20], septic shock [21], periodontitis [22], HIV-infection [23], and TB with or without HIV infection [24,25]. In the case of TB, increased levels of serum sCD14 have been described in di¡erent geographical and racial groups without ¢nding remarkable di¡erences [24,25]. In these reports, the e¡ect of anti-TB treatment on the levels of sCD14 showed contradictory results. The reason for increased levels of serum sCD14 in these diseases is still unknown. However, it is believed that the levels of sCD14 in individuals with infectious and non-infectious diseases result from the state of activation of monocytes^macrophages [20], since it is known that monocyte activation results in increased shedding of sCD14 [10]. Nevertheless, monocytes alone may not explain the increased amounts of sCD14. In this regard, other cells that produce sCD14, such as hepatocytes [11,12] and endothelial cells [13], may also contribute to the levels of sCD14 found in these diseases. Mechanisms explaining the regulation of sCD14 production are still poorly understood. However, there is evidence that sCD14 levels are under genetic control [26^29]. A polymorphism at position 3159 (CD14/C(-159)CT) from the transcription start site was previously described [28,30] and associated with a high risk of myocardial infarction. At the same time, Baldini et al. [26] showed an association of the TT genotype with increased levels of serum sCD14 in allergic individuals that correlated with low levels of total serum IgE and IL-4, suggesting that sCD14 could play a role in regulating the levels of IgE [26]. Other studies published thereafter tested the association of this CD14 polymorphism with Crohn’s disease [31], ulcerative colitis [31,32], psoriasis vulgaris [33], multiple sclerosis [34] and ischemic cerebrovascular disease [35]. These studies showed an association of the CD14 gene polymorphism with some but not all of the diseases. Studies designed to elucidate the mechanisms by which the CD14/C(-159)CT polymorphism may a¡ect the onset of diseases and the levels of serum sCD14 have been performed [11,27,29,36]. It has been reported recently that the CD14/C(-159)CT polymorphism is located at a GC box near the transcription start site, which serves as a binding site for Sp1-Sp2/Sp3 transcription factors that are involved in the regulation of CD14 gene transcription [36]. Taking these observations into account, our work assessed whether elevated levels of serum sCD14 in TB patients are in£uenced by the CD14/C(-159)CT polymorphism, and also whether this polymorphism is associated with TB and its clinical forms. Also, we assessed whether serum sCD14 levels vary in the di¡erent forms of the disease (pulmonary^pleural^miliary) and whether they change after the treatment follow-up. 2. Patients and methods 2.1. Study population Two hundred and sixty seven patients with TB, including 204 pulmonary, 33 pleural, 18 miliary, and 12 with other forms of TB, were recruited from di¡erent health units in the metropolitan area of Medellin, Colombia. Diagnoses were made by use of sputum smear staining and culturing of mycobacteria. Other diagnosis criteria such as clinical and epidemiological analysis, X ray, biopsy, and testing for levels of adenosine deaminase in pleural e¥ux [37,38] were used when direct visualisation of mycobacteria was not possible. One hundred and twelve tuberculinpositive healthy control individuals were recruited from the Facultad de Medicina at the Universidad de Antioquia, and the institutions from where the patients were recruited. All studied individuals were from Caucasian and Mestizo ethnic groups. The latter corresponds to the mix of Caucasian and Indians [39]. Individuals, who were positive for HIV infection, or with a history of cancer, autoimmune, metabolic or endocrine diseases, as well as pregnant women, were excluded from the study. A written informed consent was obtained from all subjects after explanation of the research study and guarantee of complete privacy. The study has been approved by the Ethics Committee from the Facultad de Medicina at the Universidad de Antioquia. 2.2. Serum sCD14 levels Serum was obtained from all the individuals within 2 weeks of starting anti-TB treatment, and from 17 patients with pulmonary TB, who were followed-up at 3 and 6 months after initiating anti-TB treatment. The levels of sCD14 were measured with a commercial ELISA kit, as recommended by the manufacturer (BioSource, Nivelles, Belgium). 2.3. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis of CD14 gene polymorphisms CD14 genotyping was performed in all TB patients regardless of the time of anti-TB treatment, and in patients who had already ¢nished the treatment. Genomic DNA was obtained from 10 ml of EDTA-anti-coagulated blood, and 200 ng were ampli¢ed with 1.25 U of Taq DNA polymerase (Life Technologies, Rockville, MD, USA), as described by Baldini et al. [26]. PCR products were run on FEMSIM 1661 10-3-04 E. Pacheco et al. / FEMS Immunology and Medical Microbiology 40 (2004) 207^213 2% agarose gels and visualised with ethidium bromide staining. For RFLP analysis, the obtained DNA fragment of 497 bp was digested for 16 h with 2 U AvaII (New England Biolabs, Beverly, MA, USA), which is speci¢c for the sequence CGTCC present in carriers of the CD14/-159T allele [26], and the product was electrophoresed on a 12% polyacrylamide gel. Three di¡erent banding patterns were obtained: one band of 497 bp, which corresponds to CC homozygotes, three bands of 144, 353, and 497 bp for CT heterozygotes, and two bands of 144 and 353 for TT genotype. 2.4. Statistical analysis All data was analysed using the statistics package Prism version 3.0 (GraphPad Software, San Diego, CA, USA). Allelic and genotype frequencies in cases and controls were analysed using Fisher’s exact test. Comparison of means between controls and TB patients was made by Student’s t-test. Interactions between sCD14 levels and treatment follow-up as well as interactions between sCD14 levels and di¡erent forms of TB, were analysed by one-way ANOVA, with Tukey’s Multiple Comparison Post-test. Interactions among sCD14 levels, genotypes, and TB versus controls were analysed by two-way ANOVA. 209 Fig. 1. Serum sCD14 levels in TB patients and healthy controls. Sera from tuberculin positive healthy controls and TB patients were tested for levels of sCD14 by use of a commercial ELISA kit (BioSource, Nivelles, Belgium) ; P 6 0.0001. patients, those with miliary TB had the highest sCD14 levels (pulmonary TB: 8.876 T 3.457; pleural TB : 8.811 T 2.528; miliary TB: 12.350 T 5.735 Wg ml31 ; P 6 0.03). To resolve whether sCD14 levels are modi¢ed by antiTB treatment, serum sCD14 levels from a group of 17 patients with pulmonary TB were tested at 0, 3 and 6 months of anti-TB treatment. Fig. 3 shows that levels of sCD14 signi¢cantly decreased during treatment (P 6 0.008). 3.3. Polymorphisms of the CD14 gene promoter and TB 3. Results 3.1. Characteristics of studied population Table 1 shows demographic characteristics of the population studied. Two thirds of the controls were female, while distribution within the patients’ group was more even. Patients and controls were not older than 65 years and the mean age was similar in both control and patient groups. 3.2. Serum sCD14 levels Levels of serum sCD14 from 105 TB patients and 64 PPD-positive healthy controls were tested by ELISA. Fig. 1 shows that, in agreement with previous reports, patients with TB exhibited higher levels of sCD14 compared to healthy controls (8.703 T 3.568 Wg ml31 vs. 5.189 T 1.191; P 6 0.0001). Furthermore, Fig. 2 shows that among TB Genotype and allele frequencies of 112 healthy tuberculin-positive controls and 267 TB patients were analysed for the CD14/-159 polymorphisms using PCR-RFLP. The three di¡erent genotypes (CC, CT, TT) reported previously [26] were observed after digesting the ampli¢ed DNA fragment of 497 bp with the restriction enzyme AvaII. Genotype frequencies in both control group and TB patients were in Hardy^Weinberg equilibrium. No association was found between allele and genotype frequencies and the presence of TB as a whole, or the di¡erent forms of the disease (Table 2). About half the individuals were CT heterozygous in all TB groups (range 42^59%). Thirty ¢ve percent of pulmonary TB patients were CC homozygous, whereas 23% were TT homozygous. However, no di¡erences were found when compared with the control group (Table 2). Similar results were found when all TB forms were put together in only one group. The distribution of the alleles C and T in cases and controls was similar, with the C allele ranging between 52 and 63%, Table 1 Characteristics of controls and TB patients n Controls Patients 112 267 Sex n (%) Age, mean T SD (range) male female male female 38 (33.9) 149 (55.8) 74 (66.1) 118 (44.2) 34.0 T 11.0 (19^56) 40.5 T 13.9 (17^65) 37.0 T 11.5 (19^58) 35.5 T 13.3 (15^64) FEMSIM 1661 10-3-04 210 E. Pacheco et al. / FEMS Immunology and Medical Microbiology 40 (2004) 207^213 Fig. 2. Serum sCD14 levels in di¡erent clinical forms of TB. Sera from patients with di¡erent forms of TB and tuberculin-positive healthy controls were tested for levels of sCD14, P 6 0.03. Dotted line is the mean+2SD of the control group. Fig. 3. Follow-up of serum sCD14 levels during anti-TB treatment. Sera from 17 patients with pulmonary TB were tested for sCD14 levels at 0, 3, and 6 months of anti-TB treatment; P 6 0.008. and the T allele between 37 and 48%. Again, di¡erences of allele distribution between the di¡erent groups were not signi¢cant. An association of CD14 gene polymorphisms with the levels of serum sCD14 in the group of TB patients and in the control group was also tested. As shown in Fig. 4, there was no association of serum sCD14 levels with the CD14 promoter polymorphisms, neither in controls nor in pulmonary TB patients. ing on TB patients with higher levels of serum sCD14 than healthy controls. However, the levels found in our control population were higher than in other reports [19,23,24]. These di¡erences may be associated with racial, genetic, and/or environmental factors since the individuals studied here were a highly mixed Colombian population, whereas in other studies individuals were either Africans [25] or Caucasians [19,23]. Ju¡ermans et al. [24] studied serum sCD14 levels in TB patients from di¡erent geographical and ethnic origins, including European, Asian, African and South American, but they reported no di¡erences between the ethnic groups. Our results are in agreement with the data published by Lawn et al. [25], in that the levels of sCD14 did not decrease after 3 months of anti-TB treatment. However, our study carried out a follow-up until 6 months of anti-TB treatment, and it was found that at this time serum sCD14 levels in TB patients reached those, found in control individuals. When tested for di¡erences between the three groups (0, 3, and 6 months) using Tukey’s Multiple Comparison test, no signi¢cant di¡erences were found between 0 and 3, or between 3 and 6 months. This ¢nding suggests that completing anti-TB treatment is necessary to decrease 4. Discussion The results presented herein con¢rm high levels of serum sCD14 in TB patients in a di¡erent ethnic and geographical population; show that the highest levels are found in the serum of those patients with the miliary form of the disease ; show that serum sCD14 levels decrease to normal levels after completion of anti-TB treatment; and suggest a lack of association of CD14/C(-159)CT gene polymorphisms with both the development of TB and its di¡erent clinical forms, and the increased levels of serum sCD14 in patients with pulmonary TB. These results con¢rm ¢ndings elsewhere [24,25], report- Table 2 Allele and genotype frequencies of CD14/C(-159)CT gene promoter polymorphisms in patients with di¡erent forms of TB and healthy tuberculin-positive controls Allele na f Controls C T Total Genotype CC CT TT Total n f Pulmonary TB n f Pleural TB n f Miliary TB n f Others TB forms 116 108 224 0.52 0.48 1.00 229 181 410 0.56 0.44 1.00 39 27 66 0.59 0.41 1.00 20 14 34 0.59 0.41 1.00 15 9 24 0.63 0.37 1.00 31 54 27 112 0.28 0.48 0.24 1.00 72 85 48 205 0.35 0.42 0.23 1.00 11 17 5 33 0.33 0.52 0.15 1.00 5 10 2 17 0.29 0.59 0.12 1.00 4 7 1 12 0.33 0.59 0.08 1.00 Di¡erences tested by Fisher’s Exact Test were not signi¢cant. n = number of individuals; f = gene frequency a FEMSIM 1661 10-3-04 E. Pacheco et al. / FEMS Immunology and Medical Microbiology 40 (2004) 207^213 Fig. 4. E¡ect of CD14 gene promoter genotype on serum sCD14 levels in patients with pulmonary TB. Measurement of serum sCD14 levels and genotyping of the CD14 gene promoter were performed on healthy controls and patients with pulmonary TB by use of ELISA and PCRRFLP, respectively. Di¡erences between sCD14 levels and genotype in Patients group were not signi¢cant. serum sCD14 to normal levels, and that monitoring sCD14 levels during treatment may be useful to follow up patients’ response to therapy. An interesting ¢nding of this study was the statistically signi¢cant di¡erence of sCD14 levels between the miliary form of the disease and the pulmonary form. In fact, it was found that miliary TB patients showed the highest levels of sCD14 within the whole group. Since miliary TB involves a deep immune suppression, it is worth speculating that sCD14 may play a role in the way patients respond to M. tuberculosis. In other words, sCD14 may be acting as a negative modulator of the immune system. This hypothesis is supported by previous reports [40,41], where a role of sCD14 as an immunoregulator was suggested by its ability to inhibit in vitro cell proliferation and cytokine production (IL-2, IFN-Q, IL-4) by human T cells, and to inhibit IL-6 and IgE while increasing IgG1 production by human tonsillar B cells. These ¢ndings were supported by Baldini et al. [26], who showed a negative correlation between high levels of serum sCD14 and lower levels of serum IL-4 in a population of white non-hispanic allergic patients. This report also showed that the group of TT homozygotes for the CD14/C(-159)CT polymorphism had signi¢cantly higher sCD14 levels and lower levels of IgE. Since serum from TB patients has elevated levels of sCD14, we tested whether these high levels of sCD14 and the onset of TB could be associated with the CD14/ C(-159)CT gene promoter polymorphism. We found that the distribution of the alleles in the population studied was in Hardy^Weinberg equilibrium, similarly as it has been found in other di¡erent racial and geographical populations [26,28,30,31,33,35]. Also, the allele frequencies (controls C/T : 0.52/0.48; TB: 0.56/0.44) were similar to those reported in these populations, except where an association of the CD14/C(-159)CT polymorphism with psoriasis vulgaris and myocardial infarction was tested [30, 211 33]. In these reports, Finnish and Czech individuals were studied with two thirds of the population carrying the C allele. Even though the number of patients and controls is still small, the data presented here do not show an association of the CD14/C(-159)CT polymorphism with either the onset of TB or its di¡erent forms (Table 2), or the levels of serum sCD14 (Fig. 4). This is not surprising, since contradictory data have been reported recently. These data come from studies in di¡erent human populations in which the CD14/C(-159)CT polymorphism is either associated [42] or not [35,43,44] with high serum sCD14 levels, depending on the type of study, and the ethnic groups involved. In addition, environmental gene interactions might also a¡ect the outcome of the CD14 gene polymorphism in TB, as has been suggested elsewhere [45,46]. It was reported recently [47] in patients with IgA nephropathy that those with a stable disease carried the TT genotype of the CD14/C(-159)CT polymorphism, whereas those with the CC genotype had an increased risk of disease progression. Interestingly, in vitro stimulated PBMC from controls with the TT genotype produced signi¢cantly higher levels of sCD14 and lower levels of IL-6 than those with the CC genotype [47]. It is possible that, in the case of TB, other genetic factors apart from those associated with the CD14/C(-159)CT polymorphism are a¡ecting the expression of the CD14 gene. This may be the reason why the presence of the T allele does not explain the increase of sCD14, as has been shown elsewhere [26,29,36,47]. In summary, the functional role of sCD14 in TB is still unknown, even though it is clear that higher levels of this molecule are found in the serum of such patients. With an increasing number of reports suggesting a role of sCD14 as an immunoregulatory molecule, and with the ¢ndings reported herein that miliary TB (the most aggressive form of the disease) shows the highest levels of sCD14, it is signi¢cant to research further in order to clarify the actual role of this molecule in TB. Acknowledgements We thank the following Colombian health institutions for facilitating access to TB patients within the TB control programmes : Hospital Universitario San Vicente de Pau¤l, Hospital La Mar|¤a, hospitals and health centres from Metrosalud, Instituto de Seguros Sociales, Coomeva, Comfenalco, Coopsana, Salud Total, Prosalco, and Calor de Hogar from Medell|¤n, and also Hospital Manuel Uribe Angel from Envigado, and Hospital La Cruz from Puerto Berr|¤o. We thank the patients and healthy controls who kindly agreed to participate in the research project. This study was supported by grants 1115-05-328-96 and 111505-11088 from COLCIENCIAS and the Observatorio de Ciencia y Tecnolog|¤a-Colombia. FEMSIM 1661 10-3-04 212 E. Pacheco et al. / FEMS Immunology and Medical Microbiology 40 (2004) 207^213 References [1] World Health Organization. Global Tuberculosis Control. WHO Report 2002. Geneva, Switzerland. [2] Flynn, J.L. and Chan, J. (2001) Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93^129. [3] Haziot, A., Chen, S., Ferrero, E., Low, M.G., Silber, R. and Goyert, S.M. (1988) The monocyte di¡erentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J. Immunol. 141, 547^552. [4] Jack, R.S., Grunwald, U., Stelter, F., Workalemahu, G. and Schutt, C. (1995) Both membrane-bound and soluble forms of CD14 bind to gram-negative bacteria. Eur. J. Immunol. 25, 1436^1441. [5] Pugin, J., Heumann, I.D., Tomasz, A., Kravchenko, V.V., Akamatsu, Y., Nishijima, M., Glauser, M.P., Tobias, P.S. and Ulevitch, R.J. (1994) CD14 is a pattern recognition receptor. Immunity 1, 509^516. [6] Wright, S.D., Ramos, R.A., Tobias, P.S., Ulevitch, R.J. and Mathison, J.C. (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431^1433. [7] Couturier, C., Hae¡ner-Cavaillon, N., Caro¡, M. and Kazatchkine, M.D. (1991) Binding sites for endotoxins (lipopolysaccharides) on human monocytes. J. Immunol. 147, 1899^1904. [8] Ulevitch, R.J. and Tobias, P.S. (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13, 437^457. [9] Bazil, V., Baudys, M., Hilgert, I., Stefanova, I., Low, M.G., Zbrozek, J. and Horejsi, V. (1989) Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol. Immunol. 26, 657^662. [10] Bazil, V. and Strominger, J.L. (1991) Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 147, 1567^1574. [11] Pan, Z., Zhou, L., Hetherington, C.J. and Zhang, D.E. (2000) Hepatocytes contribute to soluble CD14 production, and CD14 expression is di¡erentially regulated in hepatocytes and monocytes. J. Biol. Chem. 275, 36430^36435. [12] Su, G.L., Dorko, K., Strom, S.C., Nussler, A.K. and Wang, S.C. (1999) CD14 expression and production by human hepatocytes. J. Hepatol. 31, 435^442. [13] Jersmann, H.P., Hii, C.S., Hodge, G.L. and Ferrante, A. (2001) Synthesis and surface expression of CD14 by human endothelial cells. Infect. Immun. 69, 479^485. [14] Grunwald, U., Kruger, C., Westermann, J., Lukowsky, A., Ehlers, M. and Schutt, C. (1992) An enzyme-linked immunosorbent assay for the quanti¢cation of solubilized CD14 in biological £uids. J. Immunol. Methods 155, 225^232. [15] Frey, E.A., Miller, D.S., Jahr, T.G., Sundan, A., Bazil, V., Espevik, T., Finlay, B.B. and Wright, S.D. (1992) Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 176, 1665^ 1671. [16] Pugin, J., Schurer-Maly, C.C., Leturcq, D., Moriarty, A., Ulevitch, R.J. and Tobias, P.S. (1993) Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharidebinding protein and soluble CD14. Proc. Natl. Acad. Sci. USA 90, 2744^2748. [17] Hailman, E., Vasselon, T., Kelley, M., Busse, L.A., Hu, M.C., Lichenstein, H.S., Detmers, P.A. and Wright, S.D. (1996) Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol. 156, 4384^4390. [18] Horne¡, G., Sack, U., Kalden, J.R., Emmrich, F. and Burmester, G.R. (1993) Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin. Exp. Immunol. 91, 207^213. [19] Nockher, W.A., Wigand, R., Schoeppe, W. and Scherberich, J.E. (1994) Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin. Exp. Immunol. 96, 15^19. [20] Kruger, C., Schutt, C., Obertacke, U., Joka, T., Muller, F.E., Knoller, J., Koller, M., Konig, W. and Schonfeld, W. (1991) Serum CD14 levels in polytraumatized and severely burned patients. Clin. Exp. Immunol. 85, 297^301. [21] Landmann, R., Zimmerli, W., Sansano, S., Link, S., Hahn, A., Glauser, M.P. and Calandra, T. (1995) Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J. Infect. Dis. 171, 639^644. [22] Hayashi, J., Masaka, T. and Ishikawa, I. (1999) Increased levels of soluble CD14 in sera of periodontitis patients. Infect. Immun. 67, 417^420. [23] Lien, E., Aukrust, P., Sundan, A., Muller, F., Froland, S.S. and Espevik, T. (1998) Elevated levels of serum-soluble CD14 in human immunode¢ciency virus type 1 (HIV-1) infection : correlation to disease progression and clinical events. Blood 92, 2084^2092. [24] Ju¡ermans, N.P., Verbon, A., van Deventer, S.J., Buurman, W.A., van Deutekom, H., Speelman, P. and van der, P.T. (1998) Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. J. Infect. Dis. 178, 1839^1842. [25] Lawn, S.D., Labeta, M.O., Arias, M., Acheampong, J.W. and Grif¢n, G.E. (2000) Elevated serum concentrations of soluble CD14 in HIV3 and HIV+ patients with tuberculosis in Africa : prolonged elevation during anti-tuberculosis treatment. Clin. Exp. Immunol. 120, 483^487. [26] Baldini, M., Lohman, I.C., Halonen, M., Erickson, R.P., Holt, P.G. and Martinez, F.D. (1999) A Polymorphism* in the 5P £anking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell Mol. Biol. 20, 976^983. [27] Pan, Z., Hetherington, C.J. and Zhang, D.E. (1999) CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development. J. Biol. Chem. 274, 23242^23248. [28] Unkelbach, K., Gardemann, A., Kostrzewa, M., Philipp, M., Tillmanns, H. and Haberbosch, W. (1999) A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk pro¢le. Arterioscler. Thromb. Vasc. Biol. 19, 932^938. [29] Zhang, D.E., Hetherington, C.J., Tan, S., Dziennis, S.E., Gonzalez, D.A., Chen, H.M. and Tenen, D.G. (1994) Sp1 is a critical factor for the monocytic speci¢c expression of human CD14. J. Biol. Chem. 269, 11425^11434. [30] Hubacek, J.A., Rothe, G., Pit’ha, J., Skodova, Z., Stanek, V., Poledne, R. and Schmitz, G. (1999) C(-260)CT polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 99, 3218^3220. [31] Klein, W., Tromm, A., Griga, T., Fricke, H., Folwaczny, C., Hocke, M., Eitner, K., Marx, M., Duerig, N. and Epplen, J.T. (2002) A polymorphism in the CD14 gene is associated with Crohn disease. Scand. J. Gastroenterol. 37, 189^191. [32] Obana, N., Takahashi, S., Kinouchi, Y., Negoro, K., Takagi, S., Hiwatashi, N. and Shimosegawa, T. (2002) Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand. J. Gastroenterol. 37, 699^704. [33] Karhukorpi, J., Ikaheimo, I., Karvonen, J. and Karttunen, R. (2002) Promoter region polymorphism of the CD14 gene (C-159T) is not associated with psoriasis vulgaris. Eur. J. Immunogenet. 29, 57^60. [34] Brettschneider, J., Ecker, D., Bitsch, A., Bahner, D., Bogumil, T., Dressel, A., Elitok, E., Kitze, B., Poser, S., Weber, F. and Tumani, H. (2002) The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta1b. J. Neuroimmunol. 133, 193^197. [35] Ito, D., Murata, M., Tanahashi, N., Sato, H., Sonoda, A., Saito, I., Watanabe, K. and Fukuuchi, Y. (2000) Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke 31, 2661^2664. [36] LeVan, T.D., Bloom, J.W., Bailey, T.J., Karp, C.L., Halonen, M., FEMSIM 1661 10-3-04 E. Pacheco et al. / FEMS Immunology and Medical Microbiology 40 (2004) 207^213 [37] [38] [39] [40] [41] Martinez, F.D. and Vercelli, D. (2001) A common single nucleotide polymorphism in the CD14 promoter decreases the a⁄nity of Sp protein binding and enhances transcriptional activity. J. Immunol. 167, 5838^5844. Restrepo, L.M., Paris, S.C., Merizalde, G., Sanchez, F.O., Mesa, G. and Garcia, L.F. (1994) Nitrites, adenosine deaminase and lymphocyte proliferation in tuberculosis pleurisy. Immunol. Infect. Dis. 4, 197^201. Segura, R.M., Pascual, C., Ocana, I., Martinez-Vazquez, J.M., Ribera, E., Ruiz, I. and Pelegri, M.D. (1989) Adenosine deaminase in body £uids: a useful diagnostic tool in tuberculosis. Clin. Biochem. 22, 141^148. Carvajal-Carmona, L.G., Opho¡, R., Service, S., Hartiala, J., Molina, J., Leon, P., Ospina, J., Bedoya, G., Freimer, N. and Ruiz-Linares, A. (2003) Genetic demography of Antioquia (Colombia) and the Central Valley of Costa Rica. Hum. Genet. 112, 534^541. Arias, M.A., Rey Nores, J.E., Vita, N., Stelter, F., Borysiewicz, L.K., Ferrara, P. and Labeta, M.O. (2000) Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite e¡ects on IgG1 and IgE production. J. Immunol. 164, 3480^3486. Rey Nores, J.E., Bensussan, A., Vita, N., Stelter, F., Arias, M.A., Jones, M., Lefort, S., Borysiewicz, L.K., Ferrara, P. and Labeta, M.O. (1999) Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur. J. Immunol. 29, 265^276. 213 [42] Leung, T.F., Tang, N.L., Sung, Y.M., Li, A.M., Wong, G.W., Chan, I.H. and Lam, C.W. (2003) The C-159T polymorphism in the CD14 promoter is associated with serum total IgE concentration in atopic Chinese children. Pediatr. Allergy Immunol. 14, 255^260. [43] Sengler, C., Haider, A., Sommerfeld, C., Lau, S., Baldini, M., Martinez, F., Wahn, U. and Nickel, R. (2003) Evaluation of the CD14 C159 T polymorphism in the German Multicenter Allergy Study cohort. Clin. Exp. Allergy 33, 166^169. [44] Heesen, M., Blomeke, B., Schluter, B., Heussen, N., Rossaint, R. and Kunz, D. (2001) Lack of association between the 3260 CCT promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intensive Care Med. 27, 1770^1775. [45] Karhukorpi, J., Yan, Y., Niemela, S., Valtonen, J., Koistinen, P., Joensuu, T., Saikku, P. and Karttunen, R. (2002) E¡ect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin. Exp. Immunol. 128, 326^332. [46] Baldini, M., Vercelli, D. and Martinez, F.D. (2002) CD14: an example of gene by environment interaction in allergic disease. Allergy 57, 188^192. [47] Yoon, H.J., Shin, J.H., Yang, S.H., Chae, D.W., Kim, H., Lee, D.S., Kim, H.L., Kim, S., Lee, J.S. and Kim, Y.S. (2003) Association of the CD14 gene 3159C polymorphism with progression of IgA nephropathy. J. Med. Genet. 40, 104^108. FEMSIM 1661 10-3-04
© Copyright 2024 Paperzz